Onco Cell Therapy Summit

June 29 – June 30, 2022

Latest News

TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally

Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market

Recent Event

Onco Cell Therapy Summit

Latest Financial Results

FY 2021

Fiscal Year Ended December 31, 2021

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.

TC BioPharm (TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

IR Contacts

Company

TC BioPharm Limited
Maxim 1
2 Parklands Way
Holytown, Motherwell ML1 4WR
United Kingdom
T: +44 (0) 141 433 7557
info@tcbiopharm.com

Investor Relations

IR@tcbiopharm.com

Transfer Agent

Computershare Investor Services PLC